US EditionNeurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Summary by PR Newswire
7 Articles
7 Articles
All
Left
Center
2
Right
PR Newswire+6 Reposted by 6 other sources
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new patient-reported post-hoc data from the KINECT®-HD study highlighting...
·United States
Read Full ArticleCoverage Details
Total News Sources7
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
